Your session is about to expire
Plavix vs Pradaxa
Introduction
For patients with conditions that increase the risk of thrombotic events, such as atrial fibrillation or after certain types of heart surgery, medications like Plavix and Pradaxa are often prescribed to prevent blood clots. These drugs work by inhibiting different parts of the blood clotting process in your body, but both help reduce the risk of stroke and systemic embolism. Plavix (clopidogrel) is an antiplatelet medication that works by preventing platelets in your blood from sticking together to form a clot. Pradaxa (dabigatran), on the other hand, is a direct oral anticoagulant (DOAC) which acts primarily by inhibiting thrombin - one of the key enzymes necessary for blood coagulation.
Plavix vs Pradaxa Side By Side
| Attribute | Plavix | Pradaxa |
|---|---|---|
| Brand Name | Plavix | Pradaxa |
| Contraindications | Should not be taken with certain types of drugs like heparin or warfarin without consulting a doctor. Use cautiously in patients with recent surgery, gastric ulcers, or those prone to falls/injuries. | Should not be taken with certain types of drugs like heparin or warfarin without consulting a doctor. Use cautiously in patients with recent surgery, gastric ulcers, or those prone to falls/injuries. |
| Cost | For brand-name, around $150 for a 30-tablet supply. For generic clopidogrel, approximately $0.10/day to $.50/day depending on quantity. | For brand-name, about $450 for a 60-capsule supply. Generic dabigatran's cost varies but averages between $3-$4/day when bought in larger quantities. |
| Generic Name | Clopidogrel | Dabigatran |
| Most Serious Side Effect | Unusual bleeding or bruising, blood in your urine or stools, coughing up blood or vomit that looks like coffee grounds, chest pain, sudden numbness or weakness on one side of the body. | Symptoms of an allergic reaction, unusual bleeding from the nose or gums, heavy menstrual periods, blood in urine or stools, coughing up blood or vomit that looks like coffee grounds, joint pain and swelling. |
| Severe Drug Interactions | Cannot be taken with certain types of drugs like heparin or warfarin without consulting a doctor due to possible dangerous interactions. | Cannot be taken with certain types of drugs like heparin or warfarin without consulting a doctor due to possible dangerous interactions. |
| Typical Dose | 75 mg/day for adults to prevent blood clots following a heart attack or stroke. For acute coronary syndrome, an initial dose might be higher (300-600 mg), followed by a daily maintenance dosage of 75mg. | 150 mg twice daily, taken orally. For patients with moderate kidney impairment (creatinine clearance 30-50 mL/min), the recommended dose is reduced to 75 mg twice daily. |
What is Plavix?
Clopidogrel (the generic name for Plavix) is an antiplatelet medication first approved by the FDA in 1997. It works by preventing platelets, a type of blood cell, from aggregating and forming clots. It's primarily prescribed to people who have recently had a heart attack or stroke, or those diagnosed with peripheral artery disease.
On the other hand, Dabigatran etexilate (marketed as Pradaxa) is part of a newer class of anticoagulants known as direct thrombin inhibitors. Approved by the FDA in 2010, it inhibits an enzyme involved in blood clotting called thrombin.
While both medications aim to prevent harmful clots from forming in the body, they work on different elements of the clotting process; this results in varying side effect profiles and contraindications. For example, Plavix can cause bleeding and bruising more easily than usual due to its action on platelets while Pradaxa might increase risk for severe gastrointestinal problems.
What conditions is Plavix approved to treat?
Plavix and Pradaxa are both approved for the treatment of different cardiovascular conditions:
- Plavix is primarily used to prevent blood clots after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.
- Pradaxa is commonly prescribed to reduce the risk of stroke and serious blood clots in patients with atrial fibrillation not caused by a heart valve problem. It's also used for treating deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as preventing them from reoccurring.
How does Plavix help with these illnesses?
Plavix, also known as clopidogrel, helps to prevent blood clots by stopping platelets in your blood from sticking together and forming a clot. It does this by blocking a receptor on the surface of the platelets called P2Y12, thereby inhibiting the activation of platelets. Platelets are tiny cells in our blood that help form clots to stop bleeding. In certain conditions like heart disease or stroke, unwanted clots can form and block blood vessels. By preventing these harmful clots, Plavix reduces risk associated with such events.
On the other hand, Pradaxa (dabigatran etexilate) is a type of medication known as an anticoagulant or blood thinner. Instead of acting on platelets like Plavix does, it works by directly inhibiting thrombin - one of the key enzymes involved in clot formation process within the bloodstream itself. This action prevents fibrinogen conversion into fibrin - critical step for clot formation.
Both drugs play important roles in different aspects of antithrombotic therapy but their mechanisms differ significantly which may influence physician's choice depending upon individual patient’s condition and overall health status.
What is Pradaxa?
Pradaxa is a brand name for dabigatran, which is a direct thrombin inhibitor. It works by directly inhibiting the action of thrombin, an enzyme in the blood that aids in clot formation. Pradaxa was first approved by the FDA in 2010 and it's used to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation. Unlike Plavix, which reduces platelet aggregation to decrease the risk of stroke or heart attack, Pradaxa directly prevents clotting by acting on thrombin. This has implications for its side effect profile: while both drugs increase bleeding risk as a side effect due to their anti-clotting properties, Pradaxa does not cause some of the more common gastrointestinal problems associated with Plavix use such as diarrhea or indigestion. Furthermore, unlike Plavix that requires careful monitoring and dose adjustment depending on individual patient response, Pradaxa can be prescribed at fixed doses without routine coagulation monitoring making it easier for treatment management especially among elderly patients who are prone to erratic anticoagulant responses.
What conditions is Pradaxa approved to treat?
Pradaxa is a prescription medication that has been approved by the FDA for treating and reducing the risk of several conditions such as:
- Stroke and systemic embolism in people who have non-valvular atrial fibrillation
- Deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5–10 days
- To reduce the risk of recurrence of DVT and PE in patients who have already been previously treated.
How does Pradaxa help with these illnesses?
Pradaxa, like Plavix, is a medication that plays important roles in many processes in the body, particularly those related to blood clotting. It acts as a direct thrombin inhibitor and prevents the formation of clots by blocking the action of thrombin - an enzyme crucial for blood coagulation. However, Pradaxa has an edge over Plavix because it does not require regular monitoring or dietary restrictions and can be taken with or without food. Its mechanism of action makes it suitable even for patients who do not respond well to other anticoagulants such as Plavix. Moreover, unlike Plavix which only inhibits platelet aggregation (clumping together), Pradaxa directly interferes with the clotting process itself making it more effective in preventing strokes and systemic embolism.
How effective are both Plavix and Pradaxa?
Both clopidogrel (Plavix) and dabigatran (Pradaxa) have robust histories of success in preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Plavix was approved by the FDA in 1997, while Pradaxa was approved more recently, in 2010. However, they act through different mechanisms; Plavix is an antiplatelet drug that inhibits platelet aggregation to prevent clot formation, whereas Pradaxa is a direct thrombin inhibitor which directly prevents blood clots.
A notable clinical trial named RE-LY conducted a head-to-head comparison between warfarin (another anticoagulant), lower-dose dabigatran, and higher-dose dabigatran. In this study, both doses of dabigatran were found to be as effective as warfarin at reducing stroke or systemic embolism risk but had different bleeding profiles: the lower dose resulted in less bleeding than warfarin while the higher dose resulted in similar rates of major bleeds.
An extensive meta-analysis published in 2006 compared clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events across multiple studies. The analysis concluded that long-term use of clopidogrel plus aspirin provided significant protection against new ischemic events when compared with aspirin alone among patients with established vascular disease.
In terms of side effects profile, it's important to note that unlike Warfarins where vitamin K can reverse its effect quickly if there’s an excessive bleeding event occurs - until recent years we didn't have such option available for Dabigtran (Pradaxa). However since 2015 Idarucizumab has been introduced which can effectively reverse its action within minutes.
Ultimately both drugs serve as valuable options for decreasing stroke risk due to atrial fibrillation or other causes; however their differing mechanisms mean they may each be better suited to certain patient populations based on individual health factors.
Related trials for plavix and pradaxa
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Plavix typically prescribed?
Oral dosages of Plavix, also known as clopidogrel, typically start at 75 mg/day for adults to prevent blood clots following a heart attack or stroke. Studies have shown this is generally sufficient for most patients. For acute coronary syndrome, the initial dose might be higher (300-600 mg), followed by a daily maintenance dosage of 75mg. On the other hand, Pradaxa (dabigatran) is usually prescribed at a starting dose of 150mg taken twice daily for adults with atrial fibrillation and after hip or knee replacement surgery to avoid deep vein thrombosis or pulmonary embolism; however it can vary based on kidney function among other factors. As always, these doses can be adjusted under your doctor's supervision according to your treatment response and tolerance. In any case, self-medication and exceeding the maximum recommended dosage could lead to severe side effects.
At what dose is Pradaxa typically prescribed?
Pradaxa treatment is generally started at a dosage of 150 mg twice daily, taken orally. For patients with moderate kidney impairment (creatinine clearance 30-50 mL/min), the recommended dose is reduced to 75 mg twice daily. It's important not to break, chew or open the capsules as this can increase your risk of bleeding. The effect of Pradaxa peaks within two hours after intake and lasts up to 17 hours; hence it should be consistently taken approximately every 12 hours for maximum efficiency. Always consult with your physician before making any changes in dosing regimen or if there is no noticeable improvement after consistent use.
What are the most common side effects for Plavix?
Common side effects of Plavix (clopidogrel) and Pradaxa (dabigatran) can vary in nature. For Plavix, they may include:
- Easy bleeding/bruising
- Purple spots on the skin
- Allergic reactions like rash or itching
- Fatigue and weakness
For Pradaxa, common side effects might involve:
- Indigestion, stomach upset or burning
- Nausea and diarrhea
- Heartburn
Remember that these medications are used to prevent dangerous blood clots which could lead to strokes or other serious heart conditions. However, it is important for patients to be aware of any unusual signs such as coughing up blood, dark urine, black stools or unusual tiredness. Always consult with your healthcare provider if you experience any concerning symptoms whilst taking these medications.
Are there any potential serious side effects for Plavix?
While both Plavix and Pradaxa are blood thinners used to prevent clots, they come with their own set of potential side effects. For Plavix, these can include:
- Unusual bleeding or bruising (nosebleeds, bleeding gums)
- Blood in your urine or stools
- Coughing up blood or vomit that looks like coffee grounds
- Chest pain or heavy feeling
- Sudden numbness or weakness on one side of the body
For Pradaxa, the possible side effects can include:
- Easy bruising
- Unusual bleeding (nose, mouth, vagina, rectum), purple or red pinpoint spots under your skin
- Pink or brown urine; red or black stools (looks like tar)
- Coughing up blood
- Vomit that looks like coffee grounds
If you experience any of these symptoms while taking either medication it's crucial to seek immediate medical attention.
Remember: It is essential to discuss all potential risks and benefits with your healthcare provider before starting a new medication regimen.
What are the most common side effects for Pradaxa?
Pradaxa, also known as dabigatran, is an anticoagulant and comes with its own set of potential side effects. Some individuals using Pradaxa may experience:
- Gastrointestinal problems such as upset stomach, nausea, heartburn or bloating
- Easy bruising and minor bleeding (such as nosebleeds)
- More serious hemorrhage events
- Indigestion or burning sensation in the stomach
- It can occasionally cause a rash
- In some cases, it might lead to a reduction in renal function Keep in mind that while these are possible side effects of Pradaxa use, not all patients will experience them. Always consult your healthcare provider for advice tailored to your specific medical needs.
Are there any potential serious side effects for Pradaxa?
Just like any medication, Pradaxa can cause potential side effects. Some of the serious ones include:
- Symptoms of an allergic reaction such as hives; difficulty breathing; swelling of your face, lips, tongue or throat
- Unusual bleeding from the nose or gums
- Heavy menstrual periods
- Blood in urine or stools
- Coughing up blood or vomit that looks like coffee grounds
- Joint pain and swelling with discomfort and warmth
- Shortness of breath even with mild exertion
If you experience any of these symptoms while taking Pradaxa, immediately contact a healthcare professional. It's crucial to remember that this is not an exhaustive list - if you notice anything unusual about your health after starting on Pradaxa, it's always best to seek medical advice.
Contraindications for Plavix and Pradaxa?
Both Plavix and Pradaxa, along with most other anticoagulant medications, may increase the risk of bleeding. If you notice any unusual bleeding, such as from the gums or nose, dark or bloody stools, prolonged bleeding from cuts or increased menstrual flow in women, please seek immediate medical attention.
Neither Plavix nor Pradaxa can be taken if you are taking certain types of drugs like heparin or warfarin without consulting your doctor due to possible dangerous interactions. Always inform your physician about all the medications you are currently taking; some drugs need a period to clear from your system before initiating treatment with either Plavix or Pradaxa to prevent potentially harmful effects.
Moreover, both these drugs should be used cautiously in patients who have had recent surgery, gastric ulcers or those prone to falls/injuries as they can exacerbate bleeding. Also note that abrupt discontinuation of these medicines can increase the risk of blood clots leading to stroke and heart attack - hence any decision on stopping these meds needs a thorough discussion with your healthcare provider.
How much do Plavix and Pradaxa cost?
For the brand name versions of these drugs:
- The price for a 30-tablet supply of Plavix (75 mg) averages around $150, which works out to approximately $5/day.
- The price for a 60-capsule supply of Pradaxa (150 mg) is about $450, working out to approximately $7.5/day.
Thus, if your prescribed daily dose aligns with these amounts, then brand-name Plavix tends to be less expensive on a per-day treatment basis than Pradaxa. However, cost should not be the primary consideration in determining which of these anticoagulants is right for you.
For generic versions of Plavix (clopidogrel) and Pradaxa (dabigatran), costs are significantly lower:
- Clopidogrel is available in packs from 30 up to 90 tablets with an approximate cost ranging from around $0.10/day if you buy larger quantities upfront to about $.50/day.
- Dabigatran's price can vary widely depending on location and insurance coverage; however it tends still to be more costly than clopidogrel at an average daily cost between $3-$4 when bought in larger quantities.
Popularity of Plavix and Pradaxa
Clopidogrel, in generic form as well as brand names such as Plavix, was estimated to have been prescribed to about 33 million people in the US in 2020. Clopidogrel accounted for just over 20% of antiplatelet prescriptions in the US. However, it appears to be one of the most commonly used antiplatelet drugs (used to prevent heart attacks and strokes). The prevalence of clopidogrel has been generally consistent since its patent expiry around a decade ago.
Dabigatran, including brand versions such as Pradaxa, was prescribed to approximately 4 million people in the USA in 2020. In the US, dabigatran accounts for just under 15% of direct oral anticoagulant prescriptions (used primarily for stroke prevention), and a smaller percentage of overall antithrombotic drug prescriptions. Unlike traditional warfarin therapy which requires monitoring blood tests; dabigatran does not require regular testing making it more convenient for some patients. Despite this advantage over warfarin, its use hasn't seen rapid growth due largely to higher cost compared with generic warfarin.
Conclusion
Both Plavix (clopidogrel) and Pradaxa (dabigatran) have a well-established history of use in patients with conditions that predispose them to blood clots, such as atrial fibrillation. They are backed by robust clinical trials indicating their effectiveness over placebo or other anticoagulants in certain situations. Both medications work by inhibiting platelet aggregation, but they do so through different mechanisms: Plavix prevents platelets from sticking together while Pradaxa directly inhibits thrombin, a key enzyme involved in clot formation.
Pradaxa is considered an alternative to traditional therapies like warfarin for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation. It does not require regular monitoring like warfarin does. On the other hand, Plavix is often used following a heart attack or stroke to prevent further occurrences.
Both drugs are available in generic form which can lead to significant cost savings for individuals paying out-of-pocket for their medications. However, both clopidogrel and dabigatran may take some time before the full therapeutic effect becomes apparent.
The side effects profile varies between these two drugs - gastrointestinal issues are more common with Pradaxa whereas bleeding risks are present with both drugs but may be slightly higher with Pradaxa than Plavix. All patients taking these medications should closely monitor any signs of excessive bleeding or bruising and seek immediate medical attention if observed.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Ned, R. M. (2010, September 20). Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availabilityApplication: Pharmacogenomics. PLoS Currents. Public Library of Science (PLoS).http://doi.org/10.1371/currents.rrn1180
- Chu, M. W. A., Wilson, S. R., Novick, R. J., Stitt, L. W., & Quantz, M. A. (2004, November). Does Clopidogrel Increase Blood Loss Following Coronary Artery Bypass Surgery?. The Annals of Thoracic Surgery. Elsevier BV.http://doi.org/10.1016/j.athoracsur.2004.03.028
- Ganetsky, M., Babu, K. M., Salhanick, S. D., Brown, R. S., & Boyer, E. W. (2011, September 2). Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant. Journal of Medical Toxicology. Springer Science and Business Media LLC.http://doi.org/10.1007/s13181-011-0178-y
- Greig, S. L., & McKeage, K. (2014, October). Dabigatran Etexilate: A Review of Its Use in the Treatment of Acute Venous Thromboembolism and Prevention of Venous Thromboembolism Recurrence. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0304-7
- Latli, B., Kiesling, R., Aßfalg, S., Chevliakov, M., Hrapchak, M., Campbell, S., … Senanayake, C. H. (2016, May 5). Carbon‐13 and carbon‐14 labeled dabigatran etexilate and tritium labeled dabigatran. Journal of Labelled Compounds and Radiopharmaceuticals. Wiley.http://doi.org/10.1002/jlcr.3402
- Paikin, J. S., Haroun, M. J., & Eikelboom, J. W. (2011, March). Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Review of Cardiovascular Therapy. Informa UK Limited.http://doi.org/10.1586/erc.11.21
- You, X., Wu, W., Xu, J., Jiao, Z., Ke, M., Huang, P., & Lin, C. (2020, February 24). Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment. The Journal of Clinical Pharmacology. Wiley.http://doi.org/10.1002/jcph.1593
- Verma, A., Chhibber, V., Emhoff, T., & Klinger, D. (2012, July 6). Promise and challenges of anticoagulation with dabigatran. Clinical Kidney Journal. Oxford University Press (OUP).http://doi.org/10.1093/ckj/sfs068
- Ko, D. T., Krumholz, H. M., Tu, J. V., Austin, P. C., Stukel, T. A., Koh, M., … Jackevicius, C. A. (2018, March). Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1161/circoutcomes.117.004194
- Comin, J., & Kallmes, D. F. (2012, February 16). Dabigatran (Pradaxa). American Journal of Neuroradiology. American Society of Neuroradiology (ASNR).http://doi.org/10.3174/ajnr.a3000
- Zeymer, U. (2013, February 28). Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments. Cardiology and Therapy. Springer Science and Business Media LLC.http://doi.org/10.1007/s40119-013-0011-6